- Home
- NTRA
NTRA
Natera Inc.
as 07-26-2024 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 13.7B | IPO Year: | 2015 |
| Target Price: | $103.27 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.90 - $117.23 | Next Earning Date: | 08-05-2024 |
| Revenue: | $1,208,556,000 | Revenue Growth: | 39.26% |
| Revenue Growth (this year): | 35.6% | Revenue Growth (next year): | 16.96% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jul 20 '24 | Sell | $105.16 | 815 | $85,704.34 | 207,457 | SEC Form 4 |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jul 20 '24 | Sell | $105.16 | 2,638 | $277,409.71 | 210,377 | SEC Form 4 |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jun 28 '24 | Sell | $108.37 | 2,723 | $295,080.07 | 206,772 | SEC Form 4 |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jun 28 '24 | Sell | $107.73 | 24,008 | $2,586,456.26 | 226,843 | SEC Form 4 |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jun 28 '24 | Sell | $108.61 | 11,061 | $1,201,328.57 | 215,782 | SEC Form 4 |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jun 28 '24 | Sell | $109.43 | 2,431 | $266,020.44 | 213,351 | SEC Form 4 |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jun 28 '24 | Sell | $108.37 | 4,983 | $539,986.78 | 75,059 | SEC Form 4 |
| Marcus Gail Boxer | NTRA | Director | May 30 '24 | Sell | $110.17 | 2,000 | $220,330.00 | 18,634 | SEC Form 4 |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | May 28 '24 | Sell | $109.96 | 1,647 | $181,103.30 | 114,186 | SEC Form 4 |
| Chapman Rowan E | NTRA | Director | May 28 '24 | Sell | $109.09 | 4,856 | $529,728.41 | 5,005 | SEC Form 4 |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | May 28 '24 | Sell | $109.96 | 1,438 | $158,121.76 | 109,940 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 23 '24 | Sell | $107.90 | 344 | $37,118.12 | 68,738 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 23 '24 | Sell | $109.16 | 156 | $17,028.74 | 68,582 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 23 '24 | Sell | $107.77 | 264 | $28,449.96 | 68,818 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 23 '24 | Sell | $108.91 | 236 | $25,703.80 | 68,582 | SEC Form 4 |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | May 15 '24 | Sell | $106.59 | 3,459 | $368,710.03 | 222,776 | SEC Form 4 |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | May 15 '24 | Sell | $107.59 | 3,320 | $357,201.12 | 219,456 | SEC Form 4 |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | May 10 '24 | Sell | $101.55 | 5,997 | $608,998.35 | 228,498 | SEC Form 4 |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | May 10 '24 | Sell | $102.91 | 9,398 | $967,151.94 | 219,100 | SEC Form 4 |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | May 10 '24 | Sell | $104.03 | 4,255 | $442,633.61 | 214,845 | SEC Form 4 |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | May 10 '24 | Sell | $108.10 | 10,350 | $1,118,783.25 | 204,495 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 10 '24 | Sell | $103.06 | 349 | $35,966.93 | 321,412 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 10 '24 | Sell | $104.60 | 990 | $103,558.85 | 320,422 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 10 '24 | Sell | $105.51 | 660 | $69,636.01 | 319,762 | SEC Form 4 |
| Sheena Jonathan | NTRA | Director | May 10 '24 | Sell | $106.32 | 611 | $64,959.26 | 319,151 | SEC Form 4 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
12 hours ago
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
Zacks
a day ago
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
GuruFocus.com
9 days ago
Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
Insider Monkey
23 days ago
Natera (NTRA) Soared After a 43% Increase In Revenue
Business Wire
24 days ago
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
Simply Wall St.
24 days ago
Natera's (NASDAQ:NTRA) investors will be pleased with their massive 314% return over the last five years
GuruFocus.com
24 days ago
Insider Sale: CEO and President Steven Chapman Sells 37,500 Shares of Natera Inc (NTRA)
Business Wire
a month ago
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.